Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 billion for the latter’s cancer drug candidate pralsetinib. Through the deal, Roche gains exclusive rights for the co-development and marketing of the investigational drug for RET-altered cancers across the world […]
Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca to assess the combination of Bcl-2 and Bruton’s Tyrosine Kinase (BTK) inhibitors in a type of lymphoma. As per the collaboration terms, Ascentage Pharma will sponsor a clinical trial to evaluate the efficacy and […]
Pinpoint Therapeutics, a US biopharma company focused on developing autophagy inhibitors for cancer treatment, has secured $1 million in debt financing led by California-based venture capital firm Kairos Ventures. The preclinical stage company was founded in 2018 through PCI Ventures, a division of the Penn Center for Innovation (PCI) at the University of Pennsylvania. It […]
MicroMedicine, a US life sciences technology company, will launch Sorterra Cell Isolation System, a white blood cell isolation technology, at the 34th Society for Immunotherapy of Cancer (SITC) annual conference to be held from November 6-10 in National Harbour, Maryland. Sorterra Cell Isolation System will separate white blood cells from human peripheral blood preserving sample […]
US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per the latest pharma acquisition news. The Beijing-based BeiGene is a research-based, oncology-focused biotechnology company, which is engaged in developing molecularly targeted and immuno-oncology drug candidates for cancer treatment. The transaction […]
Eli Lilly and Company, the US-based pharmaceutical giant, has finalised its $8 billion acquisition of Connecticut-based biopharmaceutical firm Loxo Oncology, a move expected to significantly enhance its oncology portfolio. The deal, initially announced in January 2019, marks a pivotal step in Lilly’s strategy to focus on precision medicines tailored for cancers driven by specific gene […]
Bexion Pharmaceuticals has launched part 3 of its phase 1 clinical trial for BXQ-350, an investigational cancer treatment aimed at advancing the fight against solid tumors. This milestone marks a significant step forward for the US-based pharma company, which has been diligently working to explore the therapeutic potential of BXQ-350. The phase 1 trial, still […]
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to include the treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine, and dacarbazine) for adult patients. This new approval is a significant milestone for both Takeda and the Hodgkin lymphoma community, as it […]
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused biopharmaceutical company based in Waltham, Massachusetts. This strategic acquisition, which was first announced in December 2018, is expected to significantly bolster GSK’s presence in the oncology sector, reinforcing its pharmaceutical business and enhancing its pipeline and commercial […]
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a significant boost to Pfizer’s lung cancer drug, Vizimpro (dacomitinib), recommending its approval as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This recommendation specifically targets patients with epidermal growth factor receptor […]